SCHEMBL13008693

SCHEMBL13008693

COC(=O)CSc1ccc(C(C)(C)C)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.65
SMN1; SMN2 Q16637 5/20 0.64
MAPT P10636 6/20 0.54
KDM4E B2RXH2 2/20 0.54
GLA P06280 2/20 0.54
CYP1A2 P05177 1/20 0.54
CYP3A4 P08684 1/20 0.54
GAA P10253 1/20 0.54
CYP2C9 P11712 1/20 0.54
CYP2C19 P33261 1/20 0.54
LMNA P02545 3/20 0.47
HSD17B10 Q99714 5/20 0.46
HPGD P15428 4/20 0.46
TP53 P04637 2/20 0.46
MAPK1 P28482 4/20 0.45
ALOX15 P16050 3/20 0.45
APEX1 P27695 1/20 0.45
RECQL P46063 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
RXFP1 Q9HBX9 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15299569 0.87 MAPT (0.51) ALDH1A1SMN1; SMN2MAPTKDM4EGLA
SCHEMBL15426812 0.82 MAPT (0.55) ALDH1A1SMN1; SMN2MAPTKDM4EGLA
SCHEMBL5279108 0.80 ALDH1A1 (0.71) ALDH1A1SMN1; SMN2MAPTGAAHSD17B10
SCHEMBL6239095 0.80 MAPT (0.54) ALDH1A1SMN1; SMN2MAPTKDM4EGLA
SCHEMBL31757028 0.80 ALDH1A1 (0.71) ALDH1A1SMN1; SMN2MAPTKDM4ECYP1A2
SCHEMBL15549840 0.79 HSD17B10 (0.57) ALDH1A1SMN1; SMN2MAPTKDM4EGLA
SCHEMBL3112575 0.79 MAPT (0.53) ALDH1A1SMN1; SMN2MAPTKDM4EGLA
SCHEMBL2378422 0.79 SMN1; SMN2 (0.59) ALDH1A1SMN1; SMN2MAPTKDM4EGLA
SCHEMBL874798 0.79 MAPT (0.53) ALDH1A1SMN1; SMN2MAPTKDM4EGLA
SCHEMBL6764561 0.78 FFAR1 (0.61) ALDH1A1SMN1; SMN2MAPTKDM4EGLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100317653-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS ASTRAZENECA AB (SE) 2010-12-16 US disclosed
US-7795283-B2 Oxadiazole derivative as DGAT inhibitors ASTRAZENECA AB (SE) 2010-09-14 US disclosed
US-20080096874-A1 Oxadiazole Derivative as Dgat Inhibitors ASTRAZENECA AB (SE) 2008-04-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100317653-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS DGAT1, DGAT2, GPR119 ALDH1A1 314/4885SMN1; SMN2 4452/4885MAPT 2115/4885
US-20080096874-A1 Oxadiazole Derivative as Dgat Inhibitors DGAT1, DGAT2, GPR119 ALDH1A1 303/4885SMN1; SMN2 4458/4885MAPT 1986/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.